trending Market Intelligence /marketintelligence/en/news-insights/trending/qtuR3atUHSJtUc6UFgd9pg2 content esgSubNav
In This List

Roche collaborates with Warp Drive to discover antibiotics

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Roche collaborates with Warp Drive to discover antibiotics

Roche Holding AG is collaborating with Warp Drive Bio Inc. to discover and develop multiple antibiotics.

Under the collaboration, Warp Drive will deploy its proprietary Genome Mining Platform to advance multiple classes of antibiotics with activity against clinically important, drug-resistant, Gram-negative pathogens.

Roche will receive an option to acquire global license to develop and commercialize certain antibiotics developed under the collaboration.

Warp Drive will receive $87 million in up-front payment and will be eligible to receive up to $300 million in specific clinical, regulatory and sales milestones on products licensed to Roche. Warp Drive will also be eligible for royalties on future net sales.

Warp Drive is identifying and evaluating over 100 classes of potential antibiotics that were previously undiscovered and thus never analyzed for their impact on human health.